{"schemaVersion":"peptidescanner-evidence-bundle/v1","canonicalUrl":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json","manifestUrl":"https://peptidescanner.com/evidence/v1/manifest.json","peptide":{"slug":"larazotide","name":"Larazotide","url":"https://peptidescanner.com/peptides/larazotide/"},"addressing":"objects is keyed by objectPathId. A URL fragment #<objectPathId> on this file names one evidence object. Every version of a record is placed in the bundle of the record's current first peptide.","objectCount":13,"objects":{"clinicaltrials-gov-nct00362856-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct00362856-larazotide:v1","objectPathId":"clinicaltrials-gov-nct00362856-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct00362856-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00362856-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#clinicaltrials-gov-nct00362856-larazotide-v1"},"story":{"slug":"clinicaltrials-gov-nct00362856-larazotide","version":1,"domain":"Clinical trials","dateInSource":"2017-09-12","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT00362856","sourceIds":["ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b"]}],"sources":[{"id":"ctg-observation-nct00362856-2017-09-12-4f5be39cdc6b","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT00362856 · retained source version 2017-09-12:4f5be39cdc6bc8497fbc568ebf9490ea4423961fd1d52358c2b0d7549413ce5b","url":"https://clinicaltrials.gov/study/NCT00362856"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d3429c6d9f889d6099b02f749f1ddacac4c74dd203f648c6818a602ad877de86","tierARecordSha256":"d7976022dd98f33194d47abf9e6003bd993a6e158e61bda5a68b680741b3dffc"},"integrity":{"algorithm":"sha256","contentSha256":"29aaef4a4f5950051ba815a5598490e89d9202590fe6dea3f34c66803157e826"}},"clinicaltrials-gov-nct00386165-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct00386165-larazotide:v1","objectPathId":"clinicaltrials-gov-nct00386165-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct00386165-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00386165-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#clinicaltrials-gov-nct00386165-larazotide-v1"},"story":{"slug":"clinicaltrials-gov-nct00386165-larazotide","version":1,"domain":"Clinical trials","dateInSource":"2017-09-11","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT00386165","sourceIds":["ctg-observation-nct00386165-2017-09-11-bb452dcac18a"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00386165-2017-09-11-bb452dcac18a"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00386165-2017-09-11-bb452dcac18a"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct00386165-2017-09-11-bb452dcac18a"]}],"sources":[{"id":"ctg-observation-nct00386165-2017-09-11-bb452dcac18a","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT00386165 · retained source version 2017-09-11:bb452dcac18a730567450a38143edeeb8f55b47889222f7459f0d824575171e7","url":"https://clinicaltrials.gov/study/NCT00386165"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"2e4c636e7d1d85e0b6e0bc2bde36fa47c37e566c66653fe24a39eb31823dc423","tierARecordSha256":"0d381872493386861fe7142402e9071908fb984f92c0194f047471b0bfe7ba32"},"integrity":{"algorithm":"sha256","contentSha256":"ba3846e013b3bbb7312a40eceaf9daef3139455181a6afcdebf93c5626e88b79"}},"clinicaltrials-gov-nct00386490-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct00386490-larazotide:v1","objectPathId":"clinicaltrials-gov-nct00386490-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct00386490-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00386490-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#clinicaltrials-gov-nct00386490-larazotide-v1"},"story":{"slug":"clinicaltrials-gov-nct00386490-larazotide","version":1,"domain":"Clinical trials","dateInSource":"2017-09-12","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT00386490","sourceIds":["ctg-observation-nct00386490-2017-09-12-41cd4de1f25f"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00386490-2017-09-12-41cd4de1f25f"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00386490-2017-09-12-41cd4de1f25f"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct00386490-2017-09-12-41cd4de1f25f"]}],"sources":[{"id":"ctg-observation-nct00386490-2017-09-12-41cd4de1f25f","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT00386490 · retained source version 2017-09-12:41cd4de1f25fd9d9515a95afc2bfb1f8196a6999b77cf32c57c9cd1a036e4ca3","url":"https://clinicaltrials.gov/study/NCT00386490"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"1bc212180d5c0a5682098795ba5b65b789697063079b9840ce67fbc9bdf0b178","tierARecordSha256":"59b586600e35d6ecbdfa66c86f2793e8c52e7dd216a1d7fbc77c4ee750cbc37a"},"integrity":{"algorithm":"sha256","contentSha256":"8e2461069125725ea28ed43c5fa50378bc505f956a543f7a679491d82aba0fee"}},"clinicaltrials-gov-nct00492960-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct00492960-larazotide:v1","objectPathId":"clinicaltrials-gov-nct00492960-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct00492960-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00492960-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#clinicaltrials-gov-nct00492960-larazotide-v1"},"story":{"slug":"clinicaltrials-gov-nct00492960-larazotide","version":1,"domain":"Clinical trials","dateInSource":"2017-09-20","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT00492960","sourceIds":["ctg-observation-nct00492960-2017-09-20-f2928564c524"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00492960-2017-09-20-f2928564c524"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00492960-2017-09-20-f2928564c524"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct00492960-2017-09-20-f2928564c524"]}],"sources":[{"id":"ctg-observation-nct00492960-2017-09-20-f2928564c524","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT00492960 · retained source version 2017-09-20:f2928564c524e7cc284363fe1f4567aa0996dc9d585a94409fe73d1420ea39b5","url":"https://clinicaltrials.gov/study/NCT00492960"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"060bb392af148ceb13f0d4facb2e956a88eb689af23f88e78b6274a183c8655e","tierARecordSha256":"d390b711b611da6ffc82a434fa2ec4302eafe3a0409bd7bad9ae444ed78ef21a"},"integrity":{"algorithm":"sha256","contentSha256":"20fb1e4fc5ce9c8574a2ac661faceb323725541786a2a8fac1d6d8400554e50a"}},"clinicaltrials-gov-nct00620451-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct00620451-larazotide:v1","objectPathId":"clinicaltrials-gov-nct00620451-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct00620451-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00620451-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#clinicaltrials-gov-nct00620451-larazotide-v1"},"story":{"slug":"clinicaltrials-gov-nct00620451-larazotide","version":1,"domain":"Clinical trials","dateInSource":"2017-09-20","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT00620451","sourceIds":["ctg-observation-nct00620451-2017-09-20-81258e10c690"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00620451-2017-09-20-81258e10c690"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00620451-2017-09-20-81258e10c690"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct00620451-2017-09-20-81258e10c690"]}],"sources":[{"id":"ctg-observation-nct00620451-2017-09-20-81258e10c690","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT00620451 · retained source version 2017-09-20:81258e10c6900bec7cfae8f5433436c4a9b434acb10d82bdb5e72980f777a314","url":"https://clinicaltrials.gov/study/NCT00620451"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"bc5fdd670f52c529fa8194baab4d77076210094d1584002816dca437781a356a","tierARecordSha256":"4b8d216cf8e32f9cbb4464b2baa38d33742887a2864a85ccb184eb361c3ee764"},"integrity":{"algorithm":"sha256","contentSha256":"fdab1772868811e9d0010fc5594b4350097731cf354935db2a22c68b5766bd1f"}},"clinicaltrials-gov-nct00889473-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct00889473-larazotide:v1","objectPathId":"clinicaltrials-gov-nct00889473-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct00889473-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct00889473-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#clinicaltrials-gov-nct00889473-larazotide-v1"},"story":{"slug":"clinicaltrials-gov-nct00889473-larazotide","version":1,"domain":"Clinical trials","dateInSource":"2017-09-20","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT00889473","sourceIds":["ctg-observation-nct00889473-2017-09-20-a07ae78224ec"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00889473-2017-09-20-a07ae78224ec"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct00889473-2017-09-20-a07ae78224ec"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct00889473-2017-09-20-a07ae78224ec"]}],"sources":[{"id":"ctg-observation-nct00889473-2017-09-20-a07ae78224ec","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT00889473 · retained source version 2017-09-20:a07ae78224ec0b3e8fc59e3fc68e2233c3df35626779ffa3ab87425dffa0ad6b","url":"https://clinicaltrials.gov/study/NCT00889473"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"87f97f5016fc82ed1cdfbad27f28ed37cdd2c12a912bc87ad7af18c82085b4a3","tierARecordSha256":"6741a08e8bd1e34e84ecd75c30d3708312f4108b240bcbc5fbe46cd03ca1205e"},"integrity":{"algorithm":"sha256","contentSha256":"6097f59d372502b0586e3cd4b3fb066297f3216901134ef52e02a234856639f2"}},"clinicaltrials-gov-nct01396213-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct01396213-larazotide:v1","objectPathId":"clinicaltrials-gov-nct01396213-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01396213-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct01396213-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#clinicaltrials-gov-nct01396213-larazotide-v1"},"story":{"slug":"clinicaltrials-gov-nct01396213-larazotide","version":1,"domain":"Clinical trials","dateInSource":"2017-09-20","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT01396213","sourceIds":["ctg-observation-nct01396213-2017-09-20-7ba139d36870"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct01396213-2017-09-20-7ba139d36870"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct01396213-2017-09-20-7ba139d36870"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct01396213-2017-09-20-7ba139d36870"]}],"sources":[{"id":"ctg-observation-nct01396213-2017-09-20-7ba139d36870","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT01396213 · retained source version 2017-09-20:7ba139d368702adc6d5b6390c4289e5cdbb7334b55fc7b5bd52909395c9e72f8","url":"https://clinicaltrials.gov/study/NCT01396213"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"891088e7142578f845a9a02b0ce01c73406e4addc4fc1d9148092810bb4902aa","tierARecordSha256":"47f3982529772fdcbec6665db9af7bb6684773f22deec113b042443cde89c963"},"integrity":{"algorithm":"sha256","contentSha256":"30da5251474f764276d4052bfcd755ecab7312671aac8836c23acf887818c802"}},"clinicaltrials-gov-nct05747534-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:clinicaltrials-gov-nct05747534-larazotide:v1","objectPathId":"clinicaltrials-gov-nct05747534-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/clinicaltrials-gov-nct05747534-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#clinicaltrials-gov-nct05747534-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#clinicaltrials-gov-nct05747534-larazotide-v1"},"story":{"slug":"clinicaltrials-gov-nct05747534-larazotide","version":1,"domain":"Clinical trials","dateInSource":"2026-08-18","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"ClinicalTrials.gov record NCT05747534","sourceIds":["ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47"]},{"id":"summary","text":"PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47"]},{"id":"paragraph-1","text":"PeptideScanner retained ClinicalTrials.gov record NCT05747534 at 2026-11-16T01:45:58.486Z. Its registry update date was 2026-08-18, and PeptideScanner's reviewed identity mapping was larazotide.","sourceIds":["ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47"]},{"id":"paragraph-2","text":"This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective.","sourceIds":["ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47"]}],"sources":[{"id":"ctg-observation-nct05747534-2026-08-18-2f77ae5d1d47","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT05747534 · retained source version 2026-08-18:2f77ae5d1d478910bbbe486307fa9ba66477f1edf63b0947b6ab06b6618fadda","url":"https://clinicaltrials.gov/study/NCT05747534"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"cfeb6db5628c34b98ff50fd6119d109da439427c00e7ce8e53afb40e5d8b69f1","tierARecordSha256":"33ee0486a35acdd5cab4a77f7002c5a431c776bc74e07c54e2a282de8278783f"},"integrity":{"algorithm":"sha256","contentSha256":"587f9cf0f950bac72e1cf531227c541865463c166cac3585afc864d51253ee54"}},"pubmed-pmid-23336683-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-23336683-larazotide:v1","objectPathId":"pubmed-pmid-23336683-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-23336683-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-23336683-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#pubmed-pmid-23336683-larazotide-v1"},"story":{"slug":"pubmed-pmid-23336683-larazotide","version":1,"domain":"Literature metadata","dateInSource":"2018-12-02","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"Commentary: larazotide acetate - an exciting new development for coeliac patients?","sourceIds":["pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db"]},{"id":"summary","text":"PubMed lists PMID 23336683 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db"]},{"id":"paragraph-1","text":"PubMed lists PMID 23336683 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db"]}],"sources":[{"id":"pubmed-observation-pmid-23336683-2018-12-02-064af4bba5db","name":"PubMed","sourceClass":"A","title":"Commentary: larazotide acetate - an exciting new development for coeliac patients? · retained source version 1:2018-12-02:current:064af4bba5db73da94a54b459fb12f0686fd6f6d939cfa42474a2ea3213ea29c","url":"https://pubmed.ncbi.nlm.nih.gov/23336683/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"2601d6436c1f088c8ee5fb2a767a8d57084990a4438645c0f5ce23265cca2ace","tierARecordSha256":"40618784ccae3778f836cbae865ff6ba519f65a9adf16d9f0117f4450f61adba"},"integrity":{"algorithm":"sha256","contentSha256":"cf07ff0916a1cd9f244ec738ca20b7647a1ea16d9dfebf2db7eafa3fa30c54cb"}},"pubmed-pmid-23336684-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-23336684-larazotide:v1","objectPathId":"pubmed-pmid-23336684-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-23336684-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-23336684-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#pubmed-pmid-23336684-larazotide-v1"},"story":{"slug":"pubmed-pmid-23336684-larazotide","version":1,"domain":"Literature metadata","dateInSource":"2018-12-02","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply.","sourceIds":["pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e"]},{"id":"summary","text":"PubMed lists PMID 23336684 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e"]},{"id":"paragraph-1","text":"PubMed lists PMID 23336684 in Alimentary pharmacology & therapeutics as Journal Article, Comment, with publication-date metadata of 2013-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e"]}],"sources":[{"id":"pubmed-observation-pmid-23336684-2018-12-02-38df01b65a5e","name":"PubMed","sourceClass":"A","title":"Commentary: larazotide acetate - an exciting new development for coeliac patients? Authors' reply. · retained source version 1:2018-12-02:current:38df01b65a5e9d5c13b4033b2078b9dc69a1eab54cd0af8082c74bf25b481e5f","url":"https://pubmed.ncbi.nlm.nih.gov/23336684/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"6194d5f21599dc8b765a790dd46c0893a433e7b78625cad142a2e08cf9feee5a","tierARecordSha256":"3c29af365b47952fa2555091200fa00ca434bb8d9bc152a4df0eb3ea64e20d82"},"integrity":{"algorithm":"sha256","contentSha256":"3652bad4b6cee104c53b898200c55bf3c970bfac7be5f1def688b72d56cdb330"}},"pubmed-pmid-26983338-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-26983338-larazotide:v1","objectPathId":"pubmed-pmid-26983338-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-26983338-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-26983338-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#pubmed-pmid-26983338-larazotide-v1"},"story":{"slug":"pubmed-pmid-26983338-larazotide","version":1,"domain":"Literature metadata","dateInSource":"2021-08-27","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"[Larazotide as an option in case of failure of a gluten-free diet].","sourceIds":["pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae"]},{"id":"summary","text":"PubMed lists PMID 26983338 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2016-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae"]},{"id":"paragraph-1","text":"PubMed lists PMID 26983338 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2016-02 (month precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae"]}],"sources":[{"id":"pubmed-observation-pmid-26983338-2021-08-27-1b51f8c755ae","name":"PubMed","sourceClass":"A","title":"[Larazotide as an option in case of failure of a gluten-free diet]. · retained source version 1:2021-08-27:current:1b51f8c755ae38112bf43dd63cf537268b80e3354f1473c66a7484d524a6e5da","url":"https://pubmed.ncbi.nlm.nih.gov/26983338/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"850352c984003c3057f1ac23419c30a4a816c00e39e3ac64c7b72b620c1a4316","tierARecordSha256":"66229780addef087b8a036ed3c8e49579c585580a084296605f5862fd6a703d8"},"integrity":{"algorithm":"sha256","contentSha256":"cc0cd5ca6733e659aceb7d86076658a32224a6b9915dc6455cbcbb20fe22017a"}},"pubmed-pmid-35211683-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-35211683-larazotide:v1","objectPathId":"pubmed-pmid-35211683-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-35211683-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-35211683-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#pubmed-pmid-35211683-larazotide-v1"},"story":{"slug":"pubmed-pmid-35211683-larazotide","version":1,"domain":"Literature metadata","dateInSource":"2022-03-17","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.","sourceIds":["pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e"]},{"id":"summary","text":"PubMed lists PMID 35211683 in Critical care explorations as Journal Article, with publication-date metadata of 2022-02-18 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e"]},{"id":"paragraph-1","text":"PubMed lists PMID 35211683 in Critical care explorations as Journal Article, with publication-date metadata of 2022-02-18 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e"]}],"sources":[{"id":"pubmed-observation-pmid-35211683-2022-03-17-21a6d571e71e","name":"PubMed","sourceClass":"A","title":"Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series. · retained source version 1:2022-03-17:current:21a6d571e71eae1c622448a401f96a2443ad7a49f57ddafb38ed37cb94295a3d","url":"https://pubmed.ncbi.nlm.nih.gov/35211683/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d8d1cf6fe9bde003223d9f56a7f2283bb6749c39dc407dac6ce8ff9e46afb45f","tierARecordSha256":"75394c738a2f0c1f63b4e401f560e7ae33574b470515a0bf656cf63895a05219"},"integrity":{"algorithm":"sha256","contentSha256":"cb28c8f66fefb83e4a44fe32fb4d88c4dcb4b7f8368e7b9ec1a279f01e7731dc"}},"pubmed-pmid-40737433-larazotide-v1":{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-40737433-larazotide:v1","objectPathId":"pubmed-pmid-40737433-larazotide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-40737433-larazotide/","json":"https://peptidescanner.com/evidence/v1/peptides/larazotide.json#pubmed-pmid-40737433-larazotide-v1","markdown":"https://peptidescanner.com/evidence/v1/peptides/larazotide.md#pubmed-pmid-40737433-larazotide-v1"},"story":{"slug":"pubmed-pmid-40737433-larazotide","version":1,"domain":"Literature metadata","dateInSource":"2026-08-12","sourceCheckedAt":"2026-11-16","publishedAt":"2026-11-16","peptideSlugs":["larazotide"],"peptides":[{"slug":"larazotide","url":"https://peptidescanner.com/peptides/larazotide/"}]},"claims":[{"id":"headline","text":"Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.","sourceIds":["pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4"]},{"id":"summary","text":"PubMed lists PMID 40737433 in Science translational medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-30 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4"]},{"id":"paragraph-1","text":"PubMed lists PMID 40737433 in Science translational medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2025-07-30 (day precision). PeptideScanner associated the retained record with the identity slug larazotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4"]}],"sources":[{"id":"pubmed-observation-pmid-40737433-2026-08-12-2bfb38e8b3d4","name":"PubMed","sourceClass":"A","title":"Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. · retained source version 1:2026-08-12:current:2bfb38e8b3d404ff0f81915c74aedaa11a7167350cf30b41c6ecdf8ac7c1e482","url":"https://pubmed.ncbi.nlm.nih.gov/40737433/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"f18c30f5173557ec7e34409cbbd88455b8b9241502fbea48fc06e0a2458992a3","tierARecordSha256":"b53b425b56450f34247a66fab5d392db438f544d826d0b32ca1747045b972d40"},"integrity":{"algorithm":"sha256","contentSha256":"2580a8aee1c2c359f7232d54ea09f26c79c7d9cfe6bdca9f28b5d87941e939c4"}}}}
